4:23 PM
Mar 27, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Multiple myeloma (MM)

Patient sample and mouse studies suggest inhibiting IL-18 or NLRP1 could help treat MM. In patient samples, high bone marrow plasma levels of IL-18 correlated with poor overall survival. In two mouse models of MM, systemic knockout of IL-18 or NLRP1 increased survival and decreased numbers of malignant plasma cells in the bone marrow compared with normal...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >